Tenth generic of thrombopoietin drug Revolade to enter Russian market - Новости GxP

Tenth generic of thrombopoietin drug Revolade to enter Russian market  Новости GxP

Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytop...

Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder  Novartis

GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe a...

GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe aplastic anaemia  GSK

Generic Medicine OKd by Europe for Thrombocytopenia With HCV - Medscape

Generic Medicine OKd by Europe for Thrombocytopenia With HCV  Medscape

Eltrombopag Drugs Market Share, Growth Analysis | CAGR of 7.8% - Market.us

Eltrombopag Drugs Market Share, Growth Analysis | CAGR of 7.8%  Market.us

Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocyto...

Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)  Novartis

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia - The New England Journal of Med...

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia  The New England Journal of Medicine

Novartis’ Revolade proved effective for seniors - koreabiomed.com

Novartis’ Revolade proved effective for seniors  koreabiomed.com

GSK receives marketing authorisation from the European Commission for additional Revolade - GSK

GSK receives marketing authorisation from the European Commission for additional Revolade  GSK

NICE thumbs-up for Revolade - Pharmafile

NICE thumbs-up for Revolade  Pharmafile

Novartis bags EU approvals for three ex-GSK drugs - PMLiVE

Novartis bags EU approvals for three ex-GSK drugs  PMLiVE

Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with s...

Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemia  Novartis

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia - koreabiomed.com

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia  koreabiomed.com

GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepat...

GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection  GSK

Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other...

Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies  Novartis

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designati...

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication  Novartis

Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplasti...

Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder  Novartis

Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year an...

Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP  Novartis

NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment i...

NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia  Novartis

New hope for ITP patients dashed by high drug cost - CBC

New hope for ITP patients dashed by high drug cost  CBC

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA) - Nov...

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)  Novartis

GSK guilty of off-label promotion - Pharmafile

GSK guilty of off-label promotion  Pharmafile

Novartis: Blood Disease Drugs Jakavi, Revolade Show Positive Study Results - finchannel

Novartis: Blood Disease Drugs Jakavi, Revolade Show Positive Study Results  finchannel

Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Rev...

Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis  Frontiers

Promacta receives Breakthrough Therapy designation for SAA - European Pharmaceutical Review

Promacta receives Breakthrough Therapy designation for SAA  European Pharmaceutical Review

GSK’s Promacta extends US licence - Pharmafile

GSK’s Promacta extends US licence  Pharmafile

FDA expands use of eltrombopag - MDEdge

FDA expands use of eltrombopag  MDEdge

NICE says yes to Grifols' Tavlesse for rare blood disorder ITP - pharmaphorum

NICE says yes to Grifols' Tavlesse for rare blood disorder ITP  pharmaphorum

GlaxoSmithKline guilty of promoting blood drug for unlicensed use | GSK - The Guardian

GlaxoSmithKline guilty of promoting blood drug for unlicensed use | GSK  The Guardian

Drug gets breakthrough designation for SAA - MDEdge

Drug gets breakthrough designation for SAA  MDEdge

Promacta Side Effects Can Lead To Fatal Liver Injuries, Health Canada Warns - AboutLawsuits.com

Promacta Side Effects Can Lead To Fatal Liver Injuries, Health Canada Warns  AboutLawsuits.com

How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17 - Market Realist

How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17  Market Realist

Drug Patents and their Evergreening Conundrum - Bar and Bench

Drug Patents and their Evergreening Conundrum  Bar and Bench